These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 2462467)

  • 21. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
    Schirrmacher V; Schild HJ; Gückel B; von Hoegen P
    Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transplanted tumor growth and the incidence of T-lymphocyte populations in the spleen of newcastle virus-treated mice.
    Martić AJ; Ivanković S; Antica M; Hiršl N; Jukić T; Jurin M
    Cancer Biother Radiopharm; 2015 May; 30(4):182-6. PubMed ID: 25763836
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Suggestive evidence that the highly metastatic variant ESb of the T-cell lymphoma Eb is derived from spontaneous fusion with a host macrophage.
    Larizza L; Schirrmacher V; Graf L; Pflüger E; Peres-Martinez M; Stöhr M
    Int J Cancer; 1984 Nov; 34(5):699-707. PubMed ID: 6500746
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distinct proliferative T cell clonotypes are generated in response to a murine retrovirus-induced syngeneic T cell leukemia: viral gp70 antigen-specific MT4+ clones and Lyt-2+ cytolytic clones which recognize a tumor-specific cell surface antigen.
    Matis LA; Ruscetti SK; Longo DL; Jacobson S; Brown EJ; Zinn S; Kruisbeek AM
    J Immunol; 1985 Jul; 135(1):703-13. PubMed ID: 2582053
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy.
    Bai F; Niu Z; Tian H; Li S; Lv Z; Zhang T; Ren G; Li D
    Immunol Lett; 2014; 159(1-2):36-46. PubMed ID: 24613899
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New antigens presented on tumor cells can cause immune rejection without influencing the frequency of tumor-specific cytolytic T cells.
    von Hoegen P; Altevogt P; Schirrmacher V
    Cell Immunol; 1987 Oct; 109(2):338-48. PubMed ID: 3117377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of IL-2, IL-4 and IL-6 in the growth and differentiation of tumor-specific CD4+ T helper and CD8+ T cytotoxic cells.
    Selvan RS; Nagarkatti PS; Nagarkatti M
    Int J Cancer; 1990 Jun; 45(6):1096-104. PubMed ID: 1972141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence for an underlying CD4 helper and CD8 T-cell defect in B-cell-deficient mice: failure to clear persistent virus infection after adoptive immunotherapy with virus-specific memory cells from muMT/muMT mice.
    Homann D; Tishon A; Berger DP; Weigle WO; von Herrath MG; Oldstone MB
    J Virol; 1998 Nov; 72(11):9208-16. PubMed ID: 9765468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Broadening CD4
    Filskov J; Mikkelsen M; Hansen PR; Christensen JP; Thomsen AR; Andersen P; Bukh J; Agger EM
    J Virol; 2017 Jul; 91(14):. PubMed ID: 28446674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resistance of metastatic tumor variants to tumor-specific cytotoxic T-lymphocytes not due to defects in expression of restricting major histocompatibility complex molecules in murine cells.
    Altevogt P; Leidig S; Heckl-Oestreicher B
    Cancer Res; 1984 Nov; 44(11):5305-13. PubMed ID: 6333273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of cytotoxic T lymphocyte responses against hepatitis delta virus antigens which protect against tumor formation in mice.
    Mauch C; Grimm C; Meckel S; Wands JR; Blum HE; Roggendorf M; Geissler M
    Vaccine; 2001 Oct; 20(1-2):170-80. PubMed ID: 11567762
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transfer of long-lasting tumor immunity by immune T cells from MHC congenic mice: migration, survival and tumor-protectivity of cytotoxic donor cells.
    Zangemeister-Wittke U; Schirrmacher V
    Biotherapy; 1991; 3(4):319-29. PubMed ID: 1786195
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In situ analysis of tumor-specific CTL effector and memory responses elicited by tumor vaccination.
    Schirrmacher V
    Int J Oncol; 1999 Aug; 15(2):217-27. PubMed ID: 10402230
    [TBL] [Abstract][Full Text] [Related]  

  • 34. T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine.
    Haas C; Lulei M; Fournier P; Arnold A; Schirrmacher V
    Vaccine; 2005 Mar; 23(19):2439-53. PubMed ID: 15752830
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effective anti-metastatic melanoma vaccination with tumor cells transfected with MHC genes and/or infected with Newcastle disease virus (NDV).
    Plaksin D; Porgador A; Vadai E; Feldman M; Schirrmacher V; Eisenbach L
    Int J Cancer; 1994 Dec; 59(6):796-801. PubMed ID: 7989121
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant Newcastle disease virus as a vaccine vector for cancer therapy.
    Vigil A; Martinez O; Chua MA; García-Sastre A
    Mol Ther; 2008 Nov; 16(11):1883-90. PubMed ID: 18714310
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor allograft rejection is mainly mediated by CD8+ cytotoxic T lymphocytes stimulated with class I alloantigens in cooperation with CD4+ helper T cells recognizing class II alloantigens.
    Tomita Y; Mayumi H; Eto M; Nomoto K
    J Immunol; 1990 Mar; 144(6):2425-35. PubMed ID: 1968930
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of cytotoxic T lymphocytes in the prevention of lupus-like disease occurring in a murine model of graft-vs-host disease.
    Via CS; Sharrow SO; Shearer GM
    J Immunol; 1987 Sep; 139(6):1840-9. PubMed ID: 2957440
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Different expression of Lyt differentiation antigens and cell surface glycoproteins by a murine T lymphoma line and its highly metastatic variant.
    Altevogt P; Kurnick JT; Kimura AK; Bosslet K; Schirrmacher V
    Eur J Immunol; 1982 Apr; 12(4):300-7. PubMed ID: 6124426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mucosal immunity induced by orally administered transgenic plants.
    Gómez E; Chimeno Zoth S; Carrillo E; Estela Roux M; Berinstein A
    Immunobiology; 2008; 213(8):671-5. PubMed ID: 18950595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.